Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7180226 | 0.93 | HRH3 (0.69) | HRH3SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL5203377 | 0.89 | HRH3 (1.00) | HRH3SMN1; SMN2 | |
| SCHEMBL14455196 | 0.88 | HRH3 (0.79) | HRH3 | |
| SCHEMBL5202813 | 0.87 | HRH3 (0.71) | HRH3SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL5202774 | 0.83 | HRH3 (0.76) | HRH3SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL5202949 | 0.81 | HRH3 (0.70) | HRH3SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL7179046 | 0.81 | HRH3 (0.62) | HRH3SMN1; SMN2KCNH2MCHR1 | |
| SCHEMBL5207650 | 0.80 | HRH3 (0.70) | HRH3SMN1; SMN2 | |
| SCHEMBL1706818 | 0.79 | HRH3 (0.81) | HRH3 | |
| SCHEMBL5207784 | 0.77 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | claimed |
| US-7071191-B2 | Non-imidazole aryloxypiperidines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | claimed |
| EP-1311482-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | NORTEL NETWORKS LIMITED (CA) | 2002-04-04 | — | — | US | claimed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| EP-3996707-A1 | CRYSTALLINE FORMS OF PLASMA KALLIKREIN INHIBITORS | Rezolute, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021007189-A1 | CRYSTALLINE FORMS OF PLASMA KALLIKREIN INHIBITORS | REZOLUTE, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7071191-B2 | Non-imidazole aryloxypiperidines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | APODACA RICHARD | 2005-10-13 | — | — | US | disclosed |
| EP-1311482-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | NORTEL NETWORKS LIMITED (CA) | 2002-04-04 | — | — | US | disclosed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885SMN1; SMN2 3177/4885KCNH2 703/4885 |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885SMN1; SMN2 3177/4885KCNH2 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.